BAVENCIO
Google image searchProduct monograph
Active ingredient
avelumab, 20 MG/ML
DIN: 02469723
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE USE VIAL
Schedule: Prescription / Schedule D
Company: EMD SERONO, A DIVISION OF EMD INC., CANADA
Date: 18-DEC-2017
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FF — PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors (ATC, ATC/DDD)
- L01FF04 — AVELUMAB (ATC/DDD)
Reference brand drug: Bavencio
